NCT01556282

TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.

Detailed description

Therasphere consists of glass microspheres containing a radioactive material called Yttrium-90. Therasphere is delivered into the liver tumor through a catheter placed into the hepatic artery which is the artery that provides the main blood supply to the tumor, this way delivering the radioactive material directly to the tumor and sparing the rest of the liver tissue from radiation.

Conditions

• Liver Cancer
• Portal Vein Thrombosis

Interventions

Type	Name	Description
DEVICE	TheraSphere	TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.

Timeline

• Start date: 2009-03-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2012-03-16
• Last updated: 2014-05-28

Locations

1 site across 1 country: United States